Vnitr Lek 2021, 67(8):475-478 | DOI: 10.36290/vnl.2021.122
SGLT2 inhibitors - a new pillar for the treatment of heart failure
- Interní a kardiologická klinika, Fakultní nemocnice Ostrava a Lékařská fakulta Ostravské univerzity, Ostrava
DAPA-HF and EMPEROR-REDUCED clinical trials have shown significant benefits of dapagliflozin and empagliflozin in the treatment of heart failure with reduced ejection fraction regardless of the presence or absence of diabetes mellitus. Their results support the implementation of SGLT2 inhibitors into clinical practice in patients with heart failure, due to their efficacy, safety, and minimal side effects. Their mechanism of action does not depend on the state of neurohumoral activation and SGLT2 inhibitors have a simple dosing regimen, without the need for dose titration. In addition to cardioprotective properties, SGLT2 inhibitors also have a very significant nephroprotective effect. Empagliflozin and dapagliflozin have recently been approved by regulatory authorities for the treatment of adults with symptomatic chronic heart failure with reduced ejection fraction and are becoming one of the basic pillars of treatment for these patients
Keywords: heart failure - gliflozins, STLT2 inhibitors, dapagliflozin, empagliflozin.
Published: December 9, 2021 Show citation
References
- Táborský M, Kautzner J, Linhart A et al. Chronické srdeční selhání. V Kardiologie. Mladá fronta, 2017; 738-749. ISBN 978-80-204-4434-9.
- Špinar J, Špinarová L, Vítovec J. Dapagliflozin a srdeční selhání. Cor Vasa 2020; 62: 618-623.
Go to original source... - Špinar J, Špinarová L, Vítovec J. Intervenční a akutní kardiologie 2020; 19(4): 238-241.
- Špinar J, Špinarová L, Vítovec J, Kardiol. Rev. Int Med 2017;19 (3): 195-200.
- McMurray JJV, Solomon SD, Inzucchi SE et al. DAPA‑HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21; 381(21): 1995-2008. Go to original source...
Go to PubMed... - Packer M, Anker SD, Butler J et al. EMPEROR‑Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020 Oct 8; 383(15): 1413-1424. Go to original source... Go to PubMed...
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368. Erratum in: Eur Heart J. 2021 Oct 14: PMID: 34447992. Go to original source... Go to PubMed...